When patients die from asthma they are found to have intense inflammation of the airways, with epithelial shedding and eosinophil accumulationl. Lately, many groups have studied airway inflammation in asthma of varying severities; and with the techniques of fibre-optic bronchoscopy and biopsy, bronchoalveolar lavage and sputum induction they found inflammation even in mild asthma. The inflammation of the airways is characterized by an excess of CD4 positive T lymphocytes, eosinophil accumulation and activation, a slight increase in mucosal mast cells, thickening of the basement membrane, and fragility of the airway epithelium2.
The inflammatory cells within the airways produce various mediators that directly affect the bronchial smooth muscle, vasculature, and mucus-secreting cells of the airway and signal to other cells to attract and activate them. The relative importance of these different mediators and their effects on cells is incompletely understood. We know, however, that the most important mediators causing contraction of the bronchial smooth muscle are the cysteinyl leukotrienes; and these substances may have other relevant effects such as oedema formation, mucus secretion, and induction of bronchial hyperresponsiveness3.
Drugs that antagonize leukotriene receptors or inhibit leukotriene synthesis have now been shown to be effective in clinical models of asthma such as antigen-and exerciseinduced bronchoconstriction4, and in clinical trials have improved the control of asthma5.
National6 and international7 guidelines on the management of asthma have had a major impact on treatment. However, no fundamentally new class of anti-asthmatic drugs has been introduced into clinical practice since inhaled steroids more than 20 years ago. It is likely that, within the next 2 years, both leukotriene receptor antagonists and leukotriene synthesis inhibitors will be introduced into clinical practice.
DISCOVERY OF LEUKOTRIENES
Slow-reacting substances (SRSs) were discovered by Feldberg and Kellaway in 19388 when they injected cobra venom into guineapig lung and showed that there was a contraction separate from that of histamine, with slower onset and longer duration of action. In the 1 960s Brocklehurst concluded that SRS-A was a very important allergic mediator9, but elucidation of the structure of SRS-A by Samuelsson and colleagues had to await better analytical techniquesI0. Once SRS-A had been identified as leukotrienes, a huge research effort was put into understanding the biological properties of leukotrienes and into developing drugs to antagonize their action or prevent their synthesis.
BIOCHEMISTRY OF THE LEUKOTRIENES
Leukotrienes are synthesized from arachidonic acid, which is liberated by immunological or non-immunological stimulation of various inflammatory cells11. Arachidonic acid can be metabolized either by the cyclo-oxygenase system to form prostaglandins and thromboxanes or by the 5-lipoxygenase enzyme system to form leukotrienes ( Figure 1 ). For 5lipoxygenase to function, a membrane-bound protein, 5lipoxygenase activating protein (FLAP), is requiredl2. This enzyme was originally thought essential for binding to 5lipoxygenase enzymes, but it now appears to be a docking protein for arachidonic acid1 3. Once 5-lipoxygenase has metabolized arachidonic acid to leukotrienes it is degraded and inactivated. The essential intermediate in the 5lipoxygenase enzyme system is leukotriene A4 (LTA4)-an unstable epoxide that can be converted non-enzymatically by the incorporation of water to the dihydroxyacid leukotriene B4 (LTB4) or, via the incorporation of glutathione, to the cysteinyl leukotriene C4 (LTC4). Leukotriene C4 is metabolized by v-glutamyl transferase to LTD4 and then by dipeptidases to LTE4. Leukotriene E4 is then further metabolized; however, in humans a small but constant portion of LTE4 is excreted unchanged in the urine14, and this has proved very useful in monitoring the production of leukotrienes in asthma and other diseases. to be an important mediator of purulent inflammation. LTB4 is probably an important mediator of inflammatory conditions, including rheumatoid arthritis, but its role in asthma, if any, remains unclear. Leukotriene B4 receptor antagonists have shown no effect on the changes in airway function during the early or late asthmatic responses to antigen challenge21.
Though not yet cloned, the LT receptors have been characterized pharmacologically. The cysLT 1 receptor, present on airway smooth muscle, is blocked by most of the leukotriene antagonists so far developed. LTC4, D4 and E4 all bind to this receptor. Recently a second receptor has been isolated on human pulmonary vasculature and this is not blocked by most of the existing leukotriene antagonists; the biological function of this vascular receptor is not clear22. The cysLTs have biological actions that may be relevant to asthma. They are potent contractors of bronchial smooth muscle in vitro and, when inhaled by healthy or asthmatic subjects, they cause bronchoconstriction at doses 100 or 1000 times less than histamine23-26 (they are, of course, released in smaller quantities than histamine). This bronchoconstriction is long lasting, in contrast to that induced by histamine. In addition, LTs are mucus secretagogues27 and promote oedema formation28. Inhaled leukotrienes, whilst inducing airways hyperresponsiveness in some animal models, produce conflicting results in man. Some studies suggest a small increase in bronchial hyperresponsiveness29 or a decrease in the plateau of the dose-response curve to methacholine30, while others have not shown any increase3l. A study in a small number of individuals has raised the possibility that inhaled LTE4 promotes the accumulation of eosinophils in the airways of asthmatic patients32. If this is so, cysLTs may have a direct pro-inflammatory role in asthma, with important implications for the role of cysteinyl leukotriene antagonists in treatment. The findings are consistent with work in guineapigs showing an interleukin-5 (IL-5)-dependent eosinophil accumulation after inhalation of LTD433.
There is now good evidence for the production of leukotrienes both in models of asthma and in clinical asthma. After allergen challenge of atopic asthmatic patients, there is an increase in leukotriene levels in bronchoalveolar lavage fluid34 and a rise in urinary levels of LTE4, greatest during the early asthmatic response35. In asthmatic patients, leukotrienes can be found in lavage fluid36, and in acute severe asthma leukotriene levels in the blood have been reported increased37, even though isolation of leukotrienes from blood has proved difficult. The best evidence for activation of leukotrienes during acute severe asthma attacks has come from the demonstration that urinary LTE4 concentrations are raised in patients with acute severe asthma and fall to normal during treatment35.
LEUKOTRIENE RECEPTOR ANTAGONISTS
The early leukotriene receptor antagonists such as L649,923, L648,05 1, and LYl71,883 were of disappointing potency; when tested for their ability to inhibit LTD4induced bronchoconstriction in either healthy or asthmatic individuals, they produced only a fourfold to sixfold shift to the right of the LTD4 dose-response curve3840. Since then, more potent receptor antagonists have been developed, causing up to a 100-fold shift to the right of the LTD4 doseresponse curve; they are active in both chronic asthma and clinical models of asthma (such as antigen challenge). Because leukotriene antagonists differ in their chemical structures, we can be confident that the improvements they produce are a result of their properties as leukotriene antagonists and not some unforeseen biological action. The leukotriene antagonists that have been extensively studied are oral ICI 204, 219 (zafirlukast; Accolate), which produces a shift of approximately 100-fold to the right of the LTD4 dose-response curve41; MK-57142 and its active enantiomer MK-069, montelukast (Singulair); RG-125, 2543; and ONO-1078 (pranlukast)44,45. Both zafirlukast and SKF104, 353 246 have also been investigated for activity via inhalation. Of the leukotriene receptor antagonists, zarfirlukast, montelukast and pranlukast are the most advanced in development.
LEUKOTRIENE SYNTHESIS INHIBITORS
Three effective synthesis inhibitors have been developed and tested zileuton47, BAY x 100548 and MK-88649. There seems no evidence, from studies in controlled models or in chronic asthma, that the synthesis inhibitors are more effective than the leukotriene receptor antagonists, although if LTB4 is an important mediator of asthma they might in theory be more effective in its treatment. In addition they could be more effective in diseases such as bronchitis, bronchiectasis, and cystic fibrosis where sputum levels of LTB4 are high50.
EFFECTS OF LEUKOTRIENE ANTAGONISTS AND SYNTHESIS INHIBITORS IN CLINICAL MODELS OF ASTHMA
The early development of anti-asthmatic drugs usually includes investigation of their effects on allergen challenge. The potent leukotriene receptor antagonists block some 70-80% of the early responses to inhaled allergen and about 50% of the late asthmatic response51-52. In one study, the leukotriene receptor antagonist zafirlukast seemed to attenuate the increase in bronchial hyperresponsiveness occurring after allergen challenge5l. However, the effect was small and possibly an artefact53. Some workers believe that the late asthmatic response is a model of chronic asthma and that drugs active against the late asthmatic response have anti-inflammatory properties. This is a controversial area, but if this supposition proves correct the above study may provide evidence of an antiinflammatory action for leukotriene receptor antagonists. Leukotriene receptor antagonists have also been studied in another commonly used clinical model of asthma, exercise or cold air induced bronchoconstriction, which was blocked by about 70%54,55.
What about effects of leukotriene receptor antagonists and synthesis inhibitors in clinical asthma? Zafirlukast given orally produced a 7% improvement in FEV1 in patients with impaired lung function who were using effective antiasthmatic drugs including inhaled steroids56. Moreover, a group of patients with less severe asthma who were not taking inhaled steroids showed an improvement in lung function when given an intravenous infusion of MK-57157. These results indicate that the receptor antagonists promptly remove the leukotriene-induced basal tone of the airway which is caused by the chronic activation of the 5-lipoxygenase enzyme system. This interpretation is supported by the observation that the 5-lipoxygenase inhibitor zileuton likewise improves lung function in asthmatic patients within 1 h of administration58; and this benefit is additive to that from an inhaled [2-agonist56,57 . In other words, leukotriene receptor antagonists could be useful add-on therapy in asthma. Some 2-5% of adult asthmatic patients are sensitive to aspirin. After ingestion of aspirin, bronchoconstriction develops and they exhibit both increased activation of the 5lipoxygenase system59 and an increased receptor sensitivity to leukotrienes. In these patients, leukotriene antagonists improve basal airway function60 and block the effects of inhaled lysine aspirin6l. Thus, leukotriene antagonists may be particularly beneficial in this group of patients, whose asthma is often difficult to treat.
EFFECTS OF LEUKOTRIENE RECEPTOR ANTAGONISTS AND LEUKOTRIENE SYNTHESIS INHIBITORS IN CHRONIC ASTHMA
There have been few long-term studies of leukotriene antagonists or synthesis inhibitors in asthma. One of the early weak leukotriene antagonists, LY171,883, improved FEV1 by about 10% and there was some evidence that the effect was greater in patients with severe asthma as judged by requirement for rescue /12 agonists62.
In a group of patients with mild asthma not taking inhaled steroids, zafirlukast at doses of 5, 10 and 20mg twice daily was compared with placebo. There was a dose related improvement in lung function, the high dose leading to about 10% improvement in pulmonary function with a decrease in symptom scores and decreased use of /2
agonists. There was no indication that the effect had plateaued63, so higher doses might produce greater effects.
The 5-lipoxygenase inhibitor zileuton has been investigated in a 6-week clinical trial in mild to moderately severe asthmatic patients and similar improvements in pulmonary function were apparentS8. In addition a decrease in asthma exacerbations was observed in the most severe group.
FUTURE RESEARCH
Further studies will be necessary to determine where these drugs should be used and how they will fit into asthma treatment guidelines. How will they compare with inhaled steroids, disodium cromoglycate, and theophyllines? Will they add to the effects of inhaled steroids? We also need to learn more about the mechanisms by which leukotriene antagonists work: are they simply removing the tone of an endogenous bronchoconstrictor, or are they affecting components of inflammation of the airways such as oedema formation, mucus secretion or even eosinophil recruitment? Assessment of airways inflammation by bronchial biopsy, bronchoalveolar lavage, and examination of induced sputum, and studies of airway hyperresponsiveness will help to answer these questions. In the longer term we shall want to look at asthma exacerbation rates. CONCLUSION Leukotriene receptor antagonists and 5-lipoxygenase inhibitors have shown beneficial effects in challenge models such as allergen and exercise induced asthma in patients with wheeze and decreased lung function, and in mild chronic asthma. Although some of the early leukotriene antagonists had gastrointestinal and hepatic side-effects, the more recent agents have been well tolerated for at least 6 weeks63. Within the next 1-2 years we can expect leukotriene antagonists and 5-lipoxygenase inhibitors to become available for routine clinical use indeed ONO-1078 has been approved for asthma treatment in Japan, and zafirlukast is licensed in Ireland, Finland and the USA.
What will these agents contribute in the treatment of asthma? We can only speculate, but their ability to attenuate antigen and exercise induced asthma and to improve lung function and symptoms in mild asthma could render them useful in mild asthma before the introduction of an inhaled anti-inflammatory drug. Although inhaled steroids are effective and very safe in this type of asthma, patients are still concerned about side-effects and an orally active nonsteroid might be more acceptable. Aspirin-sensitive asthma, although not common, is another condition where particular benefit might be obtained. It is also possible that leukotriene receptor antagonists, and particularly 5-lipoxygenase inhibitors, will be of benefit in other airway diseases such as chronic bronchitis, bronchiectasis, and cystic fibrosis. 24 
